Search Results for "Manufacturers"

The Drug Pricing Lab engaged Milliman to prepare a report summarizing the pricing dynamics affecting utilization of biosimilars in the current Medicare Part D marketplace and under the proposed Part D benefit design in the Build Back Better Act.

This report was commissioned by the Drug Pricing Lab.

A closer look at three of PhRMA’s most cited talking points.

The infrastructure bill includes a drug waste provision from the Recovering Excessive Funds for Unused and Needless Drugs (REFUND) Act, which requires manufacturers to rebate the amount wasted back to CMS. An estimated $3 billion over 10 years can be recouped and invested in roads, bridges, and other infrastructure initiatives.

Numerous articles and reports have trumpeted biosimilar market growth, but it's critical we do not lose sight of the sole objective for creating the biosimilar market: to reduce the cost of older biologic drugs for society and taxpayers.

Steep increases in prices and spending on prescription drugs in the United States have triggered public outrage and questions about their value.

Value-based pricing has emerged as an alternative to prices determined by what the market will bear. But which agreements are truly "value-based"?

Milliman analyzes the impact of the proposed rule to implement point of sale rebates in Medicare Part D.

Pharmacy benefit managers (PBMs), such as Express Scripts, CVS Caremark, and Optum Rx, are some of the larger companies that administer the Medicare Part D prescription drug benefit.

An overview of the original subscription-based Netflix model proposed and the proposals put forth by Louisiana and Washington.

The Drug Pricing Lab takes issue with The New York Times "Fact Check" on the recent Trump Administration proposal to pilot alternative reimbursement for Part B drugs.

An alternative payment model is proposed to support a population-level payment paradigm.

U.S. prices of common cardiovascular drugs are not consistent with the cost-effectiveness evidence.

Supply chain intermediaries, or “middlemen,” are being blamed for capturing much of the money that is often categorized as drug spending.

Pharmaceutical manufacturers push for adoption of outcomes-based contracting as a means of achieving a value-based price, but such contracts are ill-suited to do so.

What steps are needed to make outcomes-based contracting a value-based approach?

What happens when a patient uses a copay coupon?

The way Medicare Part D's benefit design shows that rebates actually increase patients' out-of-pocket costs while shifting spending from plan sponsors and manufacturers to Medicare.

Copy assistance programs may seem to benefit public health and lower the costs of drugs, but they actually raise the costs of health care in the future.

Drug companies will make $1.8 billion this year by using package sizes that promote waste.

Eli Lilly charges more than $13,000 a month for Cyramza, the newest drug to treat stomach cancer.